Cell Signaling Technology Logo - Extra Large

Mouse Interleukin-13 (mIL-13) #5242

Inquiry Info. # 5242

Please see our recommended alternatives.

    Product Information

    Product Usage Information

    Reconstitution:

    With carrier: Add sterile PBS or PBS containing 1% bovine or human serum albumin or 5-10% FBS to a final mIL-13 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.

    Carrier free: Add sterile PBS or PBS containing protein to minimize absorption of mIL-13 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock mIL-13 should be greater than 50 μg/ml.

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-13. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 12-20
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-13. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1μg mIL-13.
    Activity The bioactivity of recombinant mIL-13 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 - 20 ng/ml.
    Molecular Formula Recombinant mIL-13 contains no "tags" and the nonglycosylated protein has a calculated MW of 11,677. DTT-reduced and non-reduced protein migrate as 12-20 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal SVSLP of recombinant mIL-13 was verified by amino acid sequencing.

    Source / Purification

    Recombinant mouse IL-13 (mIL-13) Ser26-Phe131 (Accession #NP_032381) was expressed in human 293 cells at Cell Signaling Technology.

    Background

    IL-13 is produced by T cells and is important in the TH2 response. IL-13 targets include B cells, eosinophils, fibroblasts, mast cells and macrophages (1-3). IL-13 binds specifically to IL-13Rα1 that complexes with IL-4Rα to form the Type II IL-4R. Jak1 and Tyk2 are activated and signal through Stat3 and Stat6 (4). IL-13Rα2 is a different gene product, lacks the intracellular domain, does not complex with IL-4Rα and does not signal (1,4,5). The extracellular domain of IL-13Rα2 is often elevated in diseased states. IL-13 plays key roles in airway hyperresponsiveness (AHR) of allergic asthma (1,6,7) and modulates resistance to parasitic organisms (1).

    Alternate Names

    il13; T-cell activation protein P600

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.